Updating results

1130 results

Sort: Relevance | Date

Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Technology appraisal guidance Published January 2016

Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

Evidence-based recommendations on ramucirumab (Cyramza)

Technology appraisal guidance Published January 2016

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

Technology appraisal guidance Published January 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

Technology appraisal guidance Published January 2016

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

Technology appraisal guidance Published December 2015

Bortezomib for previously untreated mantle cell lymphoma (TA370)

Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

Technology appraisal guidance Published December 2015

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published September 2016

Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Technology appraisal guidance Published August 2016

Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

Technology appraisal guidance Published August 2016

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Bosutinib for previously treated chronic myeloid leukaemia (TA401)

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Technology appraisal guidance Published August 2016

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Evidence-based recommendations on nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating advanced melanoma (skin cancer)

Technology appraisal guidance Published July 2016

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)

Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

Technology appraisal guidance Published July 2016

Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del..

Technology appraisal guidance Published July 2016

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

Technology appraisal guidance Published June 2016

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma with a BRAF V600 mutation

Technology appraisal guidance Published June 2016

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Technology appraisal guidance Published June 2016

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults

Technology appraisal guidance Published May 2016

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (TA389)

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...

Technology appraisal guidance Published April 2016

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Technology appraisal guidance Published December 2016

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Technology appraisal guidance Published December 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Technology appraisal guidance Published December 2016

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Technology appraisal guidance Published November 2016

Nivolumab for previously treated advanced renal cell carcinoma (TA417)

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults

Technology appraisal guidance Published November 2016

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Technology appraisal guidance Published October 2016

Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Technology appraisal guidance Published October 2016

Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published October 2016

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

Technology appraisal guidance Published September 2016

Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

Evidence-based recommendations on necitumumab (Portrazza) for untreated advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published September 2016

Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults

Technology appraisal guidance Published September 2016

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Technology appraisal guidance Published September 2016

Pegaspargase for treating acute lymphoblastic leukaemia (TA408)

Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia

Technology appraisal guidance Published September 2016

Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

Technology appraisal guidance Published September 2016

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)

NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was

Technology appraisal guidance Published August 2017

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns

Technology appraisal guidance Published August 2017

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published August 2017

Bisphosphonates for treating osteoporosis (TA464)

Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

Technology appraisal guidance Published August 2017 Last updated July 2019

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults

Technology appraisal guidance Published August 2017

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults

Technology appraisal guidance Published July 2017

Roflumilast for treating chronic obstructive pulmonary disease (TA461)

Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis

Technology appraisal guidance Published July 2017

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults

Technology appraisal guidance Published July 2017

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Evidence-based recommendations on collagenase clostridium histolyticum (Xiapex) for treating Dupuytren’s contracture in adults

Technology appraisal guidance Published July 2017

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Carfilzomib for previously treated multiple myeloma (TA457)

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults

Technology appraisal guidance Published July 2017